Skip to content

First-in-human study of I-123 IIMU.

First-in-human study of I-123 IIMU. - First-in-human study of I-123 IIMU.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000014286
Enrollment
8
Registered
2014-06-17
Start date
2015-01-15
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Normal volunteers

Interventions

Period 8/2014 - 8/2015

Sponsors

Hokkaido University Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: Normal volunteers

Exclusion criteria

Exclusion criteria: (1) a history of hepatic or renal disease. (2) a history of hypersensitivity for medical drugs. (3) a history of drug abuse. (4) a participation of other clinical trial within 6 months before enrollment. (5) any medical treatment including vitamin drug and Kanpo-drug within 14 days before enrollment. (6) a donation of plasma to a blood bank or clinical study within 14 days before enrollment. a donation of over 200 ml whole blood to a blood bank or clinical study within 28 days before enrollment. a donation of over 400 ml whole blood to a blood bank or clinical study within 84 days before enrollment. a donation of over 800 ml whole blood to a blood bank or clinical study within 365 days before enrollment. (7) a history of iodine allergy. (8)And subjects were excluded if the investigators judged as misfit for this study.

Design outcomes

Primary

MeasureTime frame
Radiation Dosimetry, Whole-Organ Biodistribution and Safety

Countries

Japan

Contacts

Public ContactTohru Shiga

Hokkaido University Hospital Nuclear medicine

tshiga@med.hokudai.ac.jp011-706-5152

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026